NCT05752318Not yet recruiting
Analysis of the Persistence, Reservoir and HIV Latency
APRIL Study: Analysis of the Persistence, Reservoir and HIV Latency
Source: ClinicalTrials.gov · Last updated 2 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 12 Jan 2023
- Start date
- 27 Feb 2023
- Primary completion date
- 25 Jan 2027
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- HIV
- NCT number
- NCT05752318
What you commit to
- Study type: Observational
- Planned participants: 500
- From 27 Feb 2023 to the primary completion date, 25 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV-uninfected
Age
- \<18 years
Other
- Lack of social insurance
- Lack or withdraw of consent
Who the study is looking for
- HIV-infection
- Adults (\>18 years)
- Social insurance
- Informed consent
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.